soul trial oral semaglutide cardiovascular outcomes nejm 2025 results Reduces CV Events in T2DM β (NEJM, Mar 2025) Relevant for: cardiology, diabetology, nephrology, internal medicine π§ͺ T2DM + ASCVD/CKD π Oral semaglutide 14 mg vs placebo π A trial emulation in Nature
Description
semaglutide medications.
Learn the facts, risks, and alternatives for weight loss
An in vitro model system used adipocytes induced from Sirt1-null mouse embryonic fibroblasts (MEFs)
This compounded retatrutide vial provides a full 4-week supply at your prescribed weekly dose
This is not a GLP-1 receptor agonist
